Formation Bio CEO Benjamine Liu on AI-Driven Drug Development and Disrupting Pharma

Formation Bio's AI-Native Pharma Model

• 💡 Formation Bio operates as an AI-native pharma company focused on clinical trials and drug development, rather than drug discovery.
• 🚀 The company's strategy involves acquiring stalled drug candidates and using AI to advance their development.
• 🎯 These drugs are then resold to pharmaceutical partners after successful phase 2 or phase 3 trials.

Streamlining Drug Development with AI

• 🧠 Formation Bio utilizes AI systems to redesign and accelerate the drug development process, from R&D strategy to clinical trials.
• ⏱️ An AI system called Muse drastically reduces the time for tasks like patient recruitment campaigns, transforming a two-month process into minutes with human oversight.
• 📊 AI is also used for predictive modeling and generating new proteins, as seen in their partnership with OpenAI and Sanofi.

Addressing the Biotech Market Dislocation

• ⚠️ The biotech market is experiencing a dislocation, with a significant increase in discovered drugs but a stagnant number of approved drugs due to high clinical trial costs.
• 💰 Discovered drugs are less valuable until they pass phase 2 trials, making Formation Bio's focus on later-stage development strategic.
• 🤝 The company leverages human expertise from former pharma executives and VC professionals for drug selection, while simultaneously training AI models based on their decision-making processes.

The Future of Drug Development Costs

• 📈 Formation Bio aims to develop drugs at a fraction of the current cost, which averages $2.6 billion per successful drug.
• 🌍 They believe that even if this efficiency leads to job displacement in some areas, the societal benefit of lower drug development costs is worthwhile.